ArticlePPAR research2008
Regulation of Lymphocyte Function by PPARgamma: Relevance to Thyroid Eye Disease-Related Inflammation.
Article in PPAR research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Macrophage plasticity in thyroid eye disease: dual effects of inflammation and fibrosis.Frontiers in immunology · 2026Review
- Molecular pathway and mechanism responsible for the progress of thyroid-associated orbitopathy.International ophthalmology · 2025Review
- The insular cortex is not insular in thyroid eye disease: neuroimaging revelations of central-peripheral system interaction.Journal of neuroinflammation · 2024Article
- Immune checkpoints: new insights into the pathogenesis of thyroid eye disease.Frontiers in immunology · 2024Review
- Leptin receptor is a key gene involved in the immunopathogenesis of thyroid-associated ophthalmopathy.Journal of cellular and molecular medicine · 2021Article
- Critical role of mass spectrometry proteomics in tear biomarker discovery for multifactorial ocular diseases (Review).International journal of molecular medicine · 2021Review
- A data-driven approach for the discovery of biomarkers associated with thyroid eye disease.BMC ophthalmology · 2021Article
- New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.Nature reviews. Endocrinology · 2020Review
- Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future.Disease markers · 2018Review
- Rituximab in the Treatment of Thyroid Eye Disease: A Review.Neuro-ophthalmology (Aeolus Press) · 2015Review
- Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases.Journal of ophthalmology · 2015Review
- Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.The Journal of biological chemistry · 2011Article
- The aryl hydrocarbon receptor ligand ITE inhibits TGFβ1-induced human myofibroblast differentiation.The American journal of pathology · 2011Article
- Novel anti-adipogenic activity produced by human fibroblasts.American journal of physiology. Cell physiology · 2010Article
- Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease.The Journal of biological chemistry · 2010Article
- Increased generation of fibrocytes in thyroid-associated ophthalmopathy.The Journal of clinical endocrinology and metabolism · 2010Article
- The eye and thyroid disease.Current opinion in ophthalmology · 2008Review
- In Vivo Effects of Retrobulbar Bimatoprost Injection on Orbital Fat.Ophthalmic plastic and reconstructive surgeryArticle
- Thyroid associated orbitopathy.Indian journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Thyroid eye disease (TED) is an autoimmune condition in which intense inflammation leads to orbital tissue remodeling, including the accumulation of extracellular macromolecules and fat. Disease progression depends upon interactions between lymphocytes and orbital fibroblasts. These cells engage in a cycle of reciprocal activation which produces the tissue characteristics of TED. Peroxisome proliferator-activated receptor-gamma (PPARgamma) may play divergent roles in this process, both attenuating and promoting disease progression. PPARgamma has anti-inflammatory activity, suggesting that it could interrupt intercellular communication. However, PPARgamma activation is also critical to adipogenesis, making it a potential culprit in the pathological fat accumulation associated with TED. This review explores the role of PPARgamma in TED, as it pertains to crosstalk between lymphocytes and fibroblasts and the development of therapeutics targeting cell-cell interactions mediated through this signaling pathway.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.